中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

200 records (took 0.019 seconds)

    HLA HAPLOTYPES AS BIOMARKERS FOR COVID-19 SYMPTOM SEVERITY
    2.
    发明申请
    HLA HAPLOTYPES AS BIOMARKERS FOR COVID-19 SYMPTOM SEVERITY 审中-公开

    公开(公告)号：WO2022117998A1

    公开(公告)日：2022-06-09

    申请号：PCT/GB2021/053084

    申请日：2021-11-26

    Applicant: PXD LIMITED

    Inventor： LANGTON, David

    IPC: G01N33/569 ,  C12Q1/6881 ,  G01N33/82

    Abstract: The present invention relates to methods, devices and kits for identifying individuals who are at increased risk of developing severe symptoms associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The present invention also relates to methods, devices and kits for identifying individuals who have a reduced risk of developing severe symptoms associated with SARS-CoV-2 infection. In particular, it relates to the use of HLA haplotypes as biomarkers to predict disease severity in individuals infected with SARS- CoV-2.

    METHODS OF DIAGNOSING AND TREATING PARTICULAR CAUSAL COMPONENTS OF CHRONIC PAIN IN A PATIENT
    5.
    发明申请
    METHODS OF DIAGNOSING AND TREATING PARTICULAR CAUSAL COMPONENTS OF CHRONIC PAIN IN A PATIENT 审中-公开

    公开(公告)号：WO2020205745A1

    公开(公告)日：2020-10-08

    申请号：PCT/US2020/025736

    申请日：2020-03-30

    Applicant: ETHOS RESEARCH & DEVELOPMENT, LLC

    Inventor： GUNN, Joshua, Adam ,  KINCAID, Brian

    IPC: G01N33/50 ,  G01N33/68 ,  G01N33/82

    Abstract: The present disclosure teaches systems and methods of diagnosing and treating the distinct biologic components that contribute to chronic pain symptoms experienced by patients. A biologic sample is obtained from a patient. Levels of two or more biomarkers ( e.g. , methylmalonic acid, homocysteine, xanthurenic acid, 3-hydroxypropyl mercapturic acid (3-HPMA), pyroglutamate, hydroxymethylglutarate (HMG), quinolinic acid, kynurenine acid, 5-hydroxyindoleacetate (5-HIAA), vanilmandelate (VMA), and ethylmalonic acid) in the biologic sample are experimentally determined. Based on the existence of abnormal results in one or more biomarkers the patient is diagnosed as having the nerve health, oxidative stress, chronic inflammation pain, and/or neurotransmitter pain components to their chronic pain. Based on the resulting diagnoses administration of certain support compounds is directed. The patient may retest after a sufficient period of time to observe any longitudinal differences in the test results and adjust treatment accordingly. Further, the biomarker data gathered from pain-neutral and chronic pain patients (particularly those using opioid therapies) will be used to characterize biochemistries going forward.

    IN VITRO DIAGNOSTIC AND PROGNOSIS OF CONTRAST INDUCED NEPHROPATHY (CIN) IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY
    10.
    发明申请
    IN VITRO DIAGNOSTIC AND PROGNOSIS OF CONTRAST INDUCED NEPHROPATHY (CIN) IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY 审中-公开
    在对冠状动脉造影患者进行体外诊断和对比剂诱发性肾病（CIN）预后方面

    公开(公告)号：WO2015124707A1

    公开(公告)日：2015-08-27

    申请号：PCT/EP2015/053563

    申请日：2015-02-20

    Applicant: IMMUNDIAGNOSTIK AG

    Inventor： HOCHER, Prof. Dr. Berthold ,  ARMBRUSTER, Dr. Franz Paul

    IPC: G01N33/68 ,  G01N33/70 ,  G01N33/82

    CPC classification number: G01N33/6893 ,  G01N33/70 ,  G01N33/82 ,  G01N2333/47 ,  G01N2333/705 ,  G01N2800/347 ,  G01N2800/52

    Abstract: Method of diagnosis and prognosis of contrast media induced nephropathy (CIN) comprising the steps of i) taking a urine sample from a patient exposed to the application of contrast media, notably patients subjected to coronary angiography; ii) assessing the level of vitamin D binding protein (VDBP) in the urine sample obtained in step (i); iii) relating the urinary vitamin D binding protein level determined in step (ii) to a pre-selected threshold level, wherein a urinary vitamin D binding level higher than said pre-selected threshold level indicates that the patient is at risk of renal failure and in need of a dialysis treatment.

    Abstract translation: 造影剂诱导的肾病（CIN）的诊断和预后的方法包括以下步骤：i）从暴露于造影剂的患者，特别是经历冠状动脉血管造影术的患者中取出尿液样本; ii）评估在步骤（i）中获得的尿液样品中维生素D结合蛋白（VDBP）的水平; iii）将步骤（ii）中确定的尿维生素D结合蛋白水平与预先选择的阈值水平相关联，其中高于所述预先选择的阈值水平的尿维生素D结合水平指示患者处于肾衰竭的风险， 需要进行透析治疗。

Patent Agency Ranking